Education and decision support. This release does not generate doses, injection instructions, cycles, diagnoses, prescriptions, or vendor pathways.
FDA approved for defined indications
Semaglutide
- Current fit
- Worth comparing
- Evidence confidence
- high
- Functional class
- Metabolic
- Receptor certainty
- known
- Routes
- subcutaneous, oral
- Monitoring
- Medical history and contraindication screening; Glucose where clinically relevant; Adverse effects and nutrition
- Action boundary
- consult
Open evidenceFDA approved for a narrow indication
Tesamorelin
- Current fit
- Indication check required
- Evidence confidence
- high
- Functional class
- GH axis
- Receptor certainty
- known
- Routes
- subcutaneous
- Monitoring
- IGF-1; Glucose status; Product-label contraindications
- Action boundary
- clinician plan only
Open evidenceFDA approved for defined indications
Tirzepatide
- Current fit
- Worth comparing
- Evidence confidence
- high
- Functional class
- Metabolic
- Receptor certainty
- known
- Routes
- subcutaneous
- Monitoring
- Medical history and contraindication screening; Adverse effects and hydration; Nutrition and follow-up
- Action boundary
- consult
Open evidence